小牛脾提取物联合化疗治疗小细胞肺癌的临床疗效

发布时间：2019-02-16 13:17

【摘要】：目的观察小牛脾提取物注射液联合奈达铂和足叶乙甙化疗治疗小细胞肺癌(SCLC)的疗效。方法 76例SCLC患者随机分为治疗组和对照组,每组38例,治疗组给予小牛脾提取物注射液联合奈达铂和足叶乙甙治疗,对照组给予奈达铂和足叶乙甙治疗,21 d为1个周期,每2个周期治疗后进行治疗情况全面评价,比较两组的治疗临床疗效、不良反应及临床表现;观察患者治疗前后外周血的T细胞亚群、血清白细胞介素(IL)-2、转化生长因子(TGF)-β1浓度。结果治疗组和对照组的客观缓解率无明显差异(P0.05);治疗组的白细胞减少、血小板减少、恶心呕吐发生率均显著低于对照组(P0.05);治疗组的CD4+、CD56+阳性细胞百分率和CD4/CD8比值同对照组比较有显著升高(P0.05);治疗组治疗后血清IL-2浓度较治疗前显著升高(P0.05),血清TGF-β1浓度显著降低(P0.05)。结论小牛脾提取物注射液联合化疗有良好客观缓解率,改善患者的免疫功能,减轻化疗的不良反应。
[Abstract]:Objective to observe the therapeutic effect of calf splenic extract injection combined with neidplatin and etoposide chemotherapy on small cell lung cancer (SCLC). Methods Seventy-six patients with SCLC were randomly divided into treatment group (n = 38) and control group (n = 38). The treatment group was treated with Niedaplatin and etoposide, while the control group was treated with neidplatin and etoposide for a period of 21 days. After every 2 cycles of treatment, comprehensive evaluation of the treatment situation, compared the two groups of the treatment of clinical efficacy, adverse reactions and clinical manifestations; The levels of T cell subsets, serum interleukin (IL)-2 and transforming growth factor (TGF)-尾 1 were observed before and after treatment. Results there was no significant difference in the objective remission rate between the treatment group and the control group (P0.05), while the incidence of leukopenia, thrombocytopenia, nausea and vomiting in the treatment group was significantly lower than that in the control group (P0.05). The percentage of CD4, CD56 positive cells and the ratio of CD4/CD8 in the treatment group were significantly higher than those in the control group (P0.05). In the treatment group, the serum IL-2 level was significantly higher than that before treatment (P0.05), and the serum TGF- 尾 1 level was significantly decreased (P0.05). Conclusion the combination of calf spleen extract injection and chemotherapy has a good objective remission rate, improves the immune function of the patients, and alleviates the adverse reaction of chemotherapy.
【作者单位】： 泸州医学院附属医院呼吸内一科;泸州医学院附属医院急诊科;
【基金】：泸州医学院附属医院青年基金(2011-43)
【分类号】：R734.2

【相似文献】

相关期刊论文 前8条

1 仲立军,刘淑燕;影响牛脾转移因子收率的几个因素[J];泰山医学院学报;2004年04期

2 葛宏华,刘晓颖,孙莉宁,吕飒音,张磊,王立;牛脾RNA的提取和性质[J];中国生化药物杂志;2001年01期

3 吕伟华;陈明雅;张彩霞;;小牛脾提取物注射液滴注过敏反应病人的护理[J];大家健康(学术版);2014年14期

4 赖寒;;小牛脾提取物联合DP方案治疗卵巢癌的疗效观察[J];中国当代医药;2011年17期

5 张高明;张力军;姜维维;高媛;;小牛脾提取物注射液联合他克莫司乳膏治疗儿童寻常型进展期白癜风[J];实用医药杂志;2014年02期

6 朱筱勇;;小牛脾提取物注射液减少乳腺癌术后化疗的不良反应[J];肿瘤;2011年08期

7 周松晶;李玉玲;;小牛脾提取物注射液联合化疗治疗晚期乳腺癌60例临床观察[J];现代预防医学;2012年17期

8 ;[J];;年期

相关会议论文 前2条

1 邵永杰;冯艳;;牛脾胃不磨的辨证施治[A];第四届中国奶业大会论文集[C];2013年

2 滕伟卓;李玉环;于欢;王德利;;超滤前后小牛脾提取物注射液成分含量、分子量分析[A];第三届泛环渤海（七省二市）生物化学与分子生物学会——2012年学术交流会论文集[C];2012年

，

本文编号：2424487